Ilyang Pharmaceutical Co Ltd (007575) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.009x

Based on the latest financial reports, Ilyang Pharmaceutical Co Ltd (007575) has a cash flow conversion efficiency ratio of 0.009x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.26 Billion ≈ $1.53 Million USD) by net assets (₩239.41 Billion ≈ $162.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ilyang Pharmaceutical Co Ltd net asset quality index to measure how much of total assets are equity-financed.

Ilyang Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Ilyang Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 007575 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Ilyang Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilyang Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Arla Plast AB ST:ARPL	0.093x
KHD Humboldt Wedag International AG XETRA:KWG	0.191x
GnBS Engineering Co. Ltd. KQ:382800	0.162x
Q32 Bio Inc NASDAQ:QTTB	-0.137x
DMS Propertindo Tbk PT JK:KOTA	-0.003x
TDM Berhad KLSE:2054	0.043x
Highlight Event Entertainment SW:HLEE	0.226x
Sona Topas Tourism Industry JK:SONA	0.066x

Annual Cash Flow Conversion Efficiency for Ilyang Pharmaceutical Co Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Ilyang Pharmaceutical Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Ilyang Pharmaceutical Co Ltd worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩241.58 Billion ≈ $163.71 Million	₩5.61 Billion ≈ $3.81 Million	0.023x	-68.77%
2023-12-31	₩196.41 Billion ≈ $133.10 Million	₩14.62 Billion ≈ $9.91 Million	0.074x	-27.43%
2022-12-31	₩291.85 Billion ≈ $197.79 Million	₩29.94 Billion ≈ $20.29 Million	0.103x	-58.41%
2021-12-31	₩271.76 Billion ≈ $184.17 Million	₩67.02 Billion ≈ $45.42 Million	0.247x	+5.08%
2020-12-31	₩244.92 Billion ≈ $165.98 Million	₩57.48 Billion ≈ $38.96 Million	0.235x	+44.44%
2019-12-31	₩222.74 Billion ≈ $150.95 Million	₩36.19 Billion ≈ $24.53 Million	0.162x	+54.17%
2018-12-31	₩209.88 Billion ≈ $142.23 Million	₩22.12 Billion ≈ $14.99 Million	0.105x	-25.94%
2017-12-31	₩210.98 Billion ≈ $142.98 Million	₩30.03 Billion ≈ $20.35 Million	0.142x	+14.64%
2016-12-31	₩217.35 Billion ≈ $147.30 Million	₩26.98 Billion ≈ $18.29 Million	0.124x	-34.96%
2015-12-31	₩211.00 Billion ≈ $142.99 Million	₩40.27 Billion ≈ $27.29 Million	0.191x	+87.97%
2014-12-31	₩183.46 Billion ≈ $124.33 Million	₩18.63 Billion ≈ $12.62 Million	0.102x	--

About Ilyang Pharmaceutical Co Ltd

KO:007575 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$90.85 Million

₩134.06 Billion KRW

Market Cap Rank

#19470 Global

#941 in Korea

Share Price

₩7380.00

Change (1 day)

+1.79%

52-Week Range

₩7000.00 - ₩13640.00

All Time High

₩141909.13